We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+36.28%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
+$257M
(+29%)
Cap. Flow
+$20M
Cap. Flow
% of AUM
1.75%
Top 10 Holdings %
Top 10 Hldgs %
86.4%
Holding
27
New
2
Increased
4
Reduced
3
Closed
1
Avg Time Held
6.7
quarters
Top 10 Avg Time Held
4.7
quarters
Top 20 Avg Time Held
6.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$74.3M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$9.85M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$5.73M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$5.02M |
| 5 |
Adverum Biotechnologies
ADVM
|
+$2.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Phathom Pharmaceuticals
PHAT
|
+$56M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$14.4M |
| 3 |
Tempest Therapeutics
TPST
|
+$7.37M |
| 4 |
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
|
+$1.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Arcutis Biotherapeutics
ARQT
$3.28B
| $319M | 28% |
10,542,790
| – | – |
2020 Q1
1 quarter
|
|
|
2
Phathom Pharmaceuticals
PHAT
$566M
| $192M | 16.84% |
5,827,415
-1,456,854
| -20% | -$56M |
2019 Q4
2 quarters
|
|
3
Passage Bio
PASG
$11.7M
| $137M | 12.02% |
250,461
| – | – |
2020 Q1
1 quarter
|
|
|
4
Vaxcyte
PCVX
$10.4B
| $73M | 6.41% |
+2,309,554
| New | +$74.3M |
2020 Q2
0 quarters
|
|
5
Mirum Pharmaceuticals
MIRM
$5.17B
| $69.4M | 6.1% |
3,566,912
| – | – |
2019 Q3
3 quarters
|
|
6
AnaptysBio
ANAB
$1.36B
| $51.7M | 4.54% |
2,316,447
| – | – |
2017 Q1
13 quarters
|
|
7
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $39.1M | 3.43% |
2,182,789
| – | – |
2019 Q2
4 quarters
|
|
8
Krystal Biotech
KRYS
$9.51B
| $37.1M | 3.26% |
895,000
| – | – |
2018 Q3
7 quarters
|
|
|
9
Iovance Biotherapeutics
IOVA
$6.57B
| $36M | 3.16% |
1,312,999
-437,666
| -25% | -$14.4M |
2016 Q2
16 quarters
|
|
|
10
DELISTED
Adverum Biotechnologies
ADVM
| $30M | 2.63% |
143,703
+15,870
| +12% | +$2.81M |
2019 Q4
2 quarters
|
|
11
DELISTED
Alpine Immune Sciences Inc
ALPN
| $25M | 2.19% |
2,571,450
| – | – |
2017 Q3
11 quarters
|
|
|
TRIL
12
DELISTED
Trillium Therapeutics Inc.
TRIL
| $22.3M | 1.96% |
2,755,000
+311,191
| +13% | +$1.93M |
2020 Q1
1 quarter
|
|
|
13
Syndax Pharmaceuticals
SNDX
$1.25B
| $19.6M | 1.72% |
1,320,045
+329,334
| +33% | +$5.02M |
2020 Q1
1 quarter
|
|
14
Collegium Pharmaceutical
COLL
$701M
| $16.5M | 1.45% |
943,666
| – | – |
2015 Q4
18 quarters
|
|
15
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $13.7M | 1.2% |
2,061,758
| – | – |
2018 Q3
7 quarters
|
|
|
APTX
16
DELISTED
Aptinyx Inc. Common Stock
APTX
| $13.3M | 1.17% |
3,190,079
| – | – |
2018 Q2
8 quarters
|
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $12.1M | 1.06% |
+2,364,500
| New | +$9.85M |
2020 Q2
0 quarters
|
|
|
18
Rocket Pharmaceuticals
RCKT
$252M
| $11.1M | 0.97% |
528,000
+318,000
| +151% | +$5.73M |
2020 Q1
1 quarter
|
|
|
ALNA
19
DELISTED
Allena Pharmaceuticals
ALNA
| $5.26M | 0.46% |
3,330,373
| – | – |
2017 Q4
10 quarters
|
|
20
DELISTED
Cidara Therapeutics
CDTX
| $4.84M | 0.43% |
65,613
| – | – |
2015 Q4
18 quarters
|
|
|
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $2.87M | 0.25% |
17,026
| – | – |
2018 Q3
7 quarters
|
|
|
SRRA
22
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $2.45M | 0.22% |
202,803
| – | – |
2015 Q4
18 quarters
|
|
23
vTv Therapeutics
VTVT
$112M
| $2.39M | 0.21% |
26,550
| – | – |
2020 Q1
1 quarter
|
|
24
DELISTED
Iterum Therapeutics
ITRM
| $1.83M | 0.16% |
102,554
| – | – |
2018 Q2
8 quarters
|
|
|
ETTX
25
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $1.04M | 0.09% |
349,953
-700,000
| -67% | -$1.91M |
2018 Q3
7 quarters
|
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q2 2020 Portfolio in Review
As of Q2 2020, Frazier Management held 27 positions worth $1.14B, up 29% from $882M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
Frazier Management's Q2 2020 filing shows 2 new, 4 increased, 3 reduced and 1 closed positions. Its largest new stake was Vaxcyte: 2,309,554 shares worth $73M. The largest sale was Phathom Pharmaceuticals, an estimated $56M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Frazier Management's largest Q2 2020 buy was Vaxcyte: 2,309,554 shares worth $73M.
- Frazier Management added most to Rocket Pharmaceuticals in Q2 2020, an estimated $5.73M increase.
- Frazier Management's biggest Q2 2020 reduction was Phathom Pharmaceuticals, cutting an estimated $56M.
- Frazier Management fully exited Tempest Therapeutics in Q2 2020, selling an estimated $7.37M.
- Frazier Management's ten largest holdings make up 86% of its $1.14B portfolio in Q2 2020.
- Frazier Management opened 2 new positions and closed 1 in Q2 2020.
- Frazier Management's portfolio value rose 29% quarter-over-quarter to $1.14B.
Based on Frazier Management's 13F filing for Q2 2020, filed 4 Aug 2020.